Loading...
XJPX
4531
Market cap39mUSD
Oct 08, Last price  
282.00JPY
1D
0.36%
1Q
7.22%
Jan 2017
11.02%
Name

Yuki Gosei Kogyo Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
6.78
P/S
0.40
EPS
41.59
Div Yield, %
2.84%
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
7.14%
Revenues
15.13b
+16.98%
10,501,403,00010,411,013,0009,602,831,0009,322,316,0008,116,579,0008,609,017,0009,422,580,00010,005,178,00010,576,448,00010,396,051,00010,073,000,00010,272,000,00010,717,000,00011,091,000,00012,361,000,00012,839,000,00012,932,000,00015,128,000,000
Net income
896m
+15.46%
261,646,000-782,875,000-567,622,000-11,963,000207,735,000337,890,00053,504,000330,209,000350,746,000355,307,000125,000,000104,000,000-42,000,000288,000,000248,000,000556,000,000776,000,000896,000,000
CFO
2.14b
+452.32%
1,543,069,000956,097,000144,956,0001,996,218,000-386,449,0001,197,487,0001,769,209,0001,384,604,000590,572,000486,083,000687,000,000656,000,0001,420,000,000352,000,0001,787,000,000668,000,000388,000,0002,143,000,000
Dividend
Mar 28, 20250 JPY/sh

Profile

Yuki Gosei Kogyo Co., Ltd. researches, develops, manufactures, and markets fine chemical products in Japan and internationally. It offers food additives, pharmaceuticals, and industrial and agricultural chemicals; and glycine, glycine compounds, nicotinic acid amide, isoniazid, drug intermediates, and cosmetic ingredients. The company also provides amino acid, pyridine, piperidine, silicon, and other compounds; DNA, nucleoside, and protamine; and active pharmaceutical ingredients. In addition, it engages in the contract manufacturing of pharmaceuticals and chemical products. Yuki Gosei Kogyo Co., Ltd. was founded in 1947 and is headquartered in Tokyo, Japan.
IPO date
Oct 02, 1962
Employees
295
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
15,128,000
16.98%
12,932,000
0.72%
12,839,000
3.87%
Cost of revenue
13,911,000
11,736,000
10,676,000
Unusual Expense (Income)
NOPBT
1,217,000
1,196,000
2,163,000
NOPBT Margin
8.04%
9.25%
16.85%
Operating Taxes
228,000
129,000
84,000
Tax Rate
18.73%
10.79%
3.88%
NOPAT
989,000
1,067,000
2,079,000
Net income
896,000
15.46%
776,000
39.57%
556,000
124.19%
Dividends
(173,000)
(152,000)
(87,000)
Dividend yield
3.01%
2.20%
1.34%
Proceeds from repurchase of equity
(75,000)
BB yield
1.31%
Debt
Debt current
4,400,000
4,629,000
4,436,000
Long-term debt
4,375,000
2,594,000
1,584,000
Deferred revenue
373,000
1,087,000
Other long-term liabilities
1,103,000
1,486,000
6,000
Net debt
5,659,000
4,510,000
3,123,000
Cash flow
Cash from operating activities
2,143,000
388,000
668,000
CAPEX
(3,342,000)
(1,834,000)
(1,158,000)
Cash from investing activities
(3,248,000)
(1,894,000)
(1,237,000)
Cash from financing activities
1,496,000
948,000
(158,000)
FCF
(985,000)
(1,662,000)
818,000
Balance
Cash
973,000
588,000
1,143,000
Long term investments
2,143,000
2,125,000
1,754,000
Excess cash
2,359,600
2,066,400
2,255,050
Stockholders' equity
7,963,000
6,009,000
8,597,000
Invested Capital
20,365,400
18,344,600
15,791,950
ROIC
5.11%
6.25%
13.72%
ROCE
5.21%
5.69%
11.60%
EV
Common stock shares outstanding
21,657
21,824
21,824
Price
265.00
-16.40%
317.00
6.73%
297.00
8.39%
Market cap
5,739,096
-17.04%
6,918,080
6.73%
6,481,857
8.39%
EV
11,398,096
11,428,080
9,604,857
EBITDA
2,251,000
2,125,000
3,091,000
EV/EBITDA
5.06
5.38
3.11
Interest
75,000
49,000
50,000
Interest/NOPBT
6.16%
4.10%
2.31%